Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17119230 | 0.95 | BACE1 (0.72) | BACE1BACE2 | |
| SCHEMBL17119119 | 0.92 | BACE1 (0.67) | BACE1BACE2 | |
| SCHEMBL16006853 | 0.87 | BACE1 (0.72) | BACE1BACE2 | |
| SCHEMBL14240115 | 0.87 | BACE1 (1.00) | BACE1BACE2 | |
| SCHEMBL15705105 | 0.87 | BACE1 (1.00) | BACE1BACE2 | |
| SCHEMBL15524741 | 0.87 | BACE1 (1.00) | BACE1BACE2 | |
| SCHEMBL17119225 | 0.86 | BACE1 (0.65) | BACE1BACE2 | |
| SCHEMBL17119279 | 0.86 | BACE1 (0.67) | BACE1BACE2 | |
| SCHEMBL360396 | 0.84 | BACE1 (1.00) | BACE1BACE2 | |
| SCHEMBL362213 | 0.84 | BACE1 (1.00) | BACE1BACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9758513-B2 | Dihydrooxazine or oxazepine derivatives having BACE1 inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2017-09-12 | — | — | US | disclosed |
| US-20170008881-A1 | DIHYDROOXAZINE OR OXAZEPINE DERIVATIVES HAVING BACE1 INHIBITORY ACTIVITY | SHIONOGI & CO (JP) | 2017-01-12 | — | — | US | disclosed |
| US-9540359-B2 | Dihydrooxazine or oxazepine derivatives having BACE1 inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2017-01-10 | — | — | US | disclosed |
| US-20150266865-A1 | DIHYDROOXAZINE OR OXAZEPINE DERIVATIVES HAVING BACE1 INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2015-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150266865-A1 | DIHYDROOXAZINE OR OXAZEPINE DERIVATIVES HAVING BACE1 INHIBITORY ACTIVITY | BACE1, APP, BACE2 | BACE1 1/4885BACE2 3/4885 |
| US-20170008881-A1 | DIHYDROOXAZINE OR OXAZEPINE DERIVATIVES HAVING BACE1 INHIBITORY ACTIVITY | BACE1, APP, BACE2 | BACE1 1/4885BACE2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.